<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Precipio Inc — News on 6ix</title>
<link>https://6ix.com/company/precipio-inc</link>
<description>Latest news and press releases for Precipio Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 12 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/precipio-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b0b778dffbe2df10fcb8.webp</url>
<title>Precipio Inc</title>
<link>https://6ix.com/company/precipio-inc</link>
</image>
<item>
<title>Precipio Announces Q4 and year-end 2025 Shareholder Update Call</title>
<link>https://6ix.com/company/precipio-inc/news/precipio-announces-q4-and-year-end-2025-shareholder-update-call-56</link>
<guid isPermaLink="true">https://6ix.com/company/precipio-inc/news/precipio-announces-q4-and-year-end-2025-shareholder-update-call-56</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>Conference Call to be held on April 2nd, 2026 at 5:00 PM EST NEW HAVEN, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company</description>
</item>
<item>
<title>Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay</title>
<link>https://6ix.com/company/precipio-inc/news/precipio-announces-publication-of-a-joint-study-with-memorial-sloan-kettering-cancer-center-highlighting-its-cutting-edge-bloodhound-bcrabl1-assay-12</link>
<guid isPermaLink="true">https://6ix.com/company/precipio-inc/news/precipio-announces-publication-of-a-joint-study-with-memorial-sloan-kettering-cancer-center-highlighting-its-cutting-edge-bloodhound-bcrabl1-assay-12</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>This is the only assay available on the market that delivers full quantification of all four clinically relevant BCR::ABL1 isoforms NEW HAVEN, Conn., March</description>
</item>
<item>
<title>Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year</title>
<link>https://6ix.com/company/precipio-inc/news/precipio-2025-unaudited-revenues-grew-to-dollar240m-a-30percent-increase-year-over-year</link>
<guid isPermaLink="true">https://6ix.com/company/precipio-inc/news/precipio-2025-unaudited-revenues-grew-to-dollar240m-a-30percent-increase-year-over-year</guid>
<pubDate>Wed, 25 Feb 2026 14:30:00 GMT</pubDate>
<description>In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1MNEW HAVEN, Conn., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces some preliminary (unaudited) financials for Q4-2025 and for its fiscal year 2025. Below are some of the key financial performance metrics for the Company. Revenue Growth – Precipio’s revenues increased from $18.5M in 2024 to $24.0M in 2025, an increase of 30% year over y</description>
</item>
<item>
<title>Precipio Takes Major Steps Toward a Clean Balance Sheet</title>
<link>https://6ix.com/company/precipio-inc/news/precipio-takes-major-steps-toward-140000409</link>
<guid isPermaLink="true">https://6ix.com/company/precipio-inc/news/precipio-takes-major-steps-toward-140000409</guid>
<pubDate>Thu, 15 Jan 2026 14:00:00 GMT</pubDate>
<description>Less than $80,000 of long-term debt, and 10,000 vendor warrants remain outstandingNEW HAVEN, Conn., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has made major strides in cleaning up its balance sheet with two major accomplishments: 1. Major obligation repaid A $1.1 million advance from Change Healthcare (“CHC”), the Company’s clearinghouse service for billing claims processing, has been repaid. CHC experienced a cybersecurity incident in 2</description>
</item>
<item>
<title>Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting</title>
<link>https://6ix.com/company/precipio-inc/news/precipio-showcase-bcr-abl1-panel-150000948</link>
<guid isPermaLink="true">https://6ix.com/company/precipio-inc/news/precipio-showcase-bcr-abl1-panel-150000948</guid>
<pubDate>Fri, 05 Dec 2025 15:00:00 GMT</pubDate>
<description>Joint study conducted with Memorial Sloan Kettering Cancer Center demonstrates clear, positive impacts on patient careNEW HAVEN, Conn., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) will be presenting at ASH the findings of a joint study conducted with scientific collaborators from Memorial Sloan Kettering in New York, evaluating Precipio’s BCR::ABL1 assay. The data from a comprehensive study includes 895 patient samples and demonstrates sup</description>
</item>
<item>
<title>Precipio Identifies Unauthorized Access to Isolated Storage; No Operational Impact</title>
<link>https://6ix.com/company/precipio-inc/news/precipio-identifies-unauthorized-access-isolated-130000336</link>
<guid isPermaLink="true">https://6ix.com/company/precipio-inc/news/precipio-identifies-unauthorized-access-isolated-130000336</guid>
<pubDate>Thu, 04 Dec 2025 13:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Precipio, Inc. reports that the Company recently identified a single, limited scope unauthorized access to a specific data folder stored within its secure cloud file environment. The incident was limited to its file storage server and did not impact any of Precipio’s operations, diagnostics processes, or customer services, and the company continued to provide its services unhindered. There was no impact to patient care; nor impact to the compan</description>
</item>
<item>
<title>Precipio Announces its Q3-2025 Financial Results</title>
<link>https://6ix.com/company/precipio-inc/news/precipio-announces-q3-2025-financial-213000899</link>
<guid isPermaLink="true">https://6ix.com/company/precipio-inc/news/precipio-announces-q3-2025-financial-213000899</guid>
<pubDate>Fri, 14 Nov 2025 21:30:00 GMT</pubDate>
<description>Over $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarterNEW HAVEN, Conn., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), filed its 10-Q report today. The following are the highlights of the Company’s financial performance and outlook for the remainder of 2025. Q3-2025 Financial Results: Revenues. Q3-2025 revenues reached $6.8M, a 30% increase YoY from $5.2M in Q3-2024, and a QoQ increase of 20% from $5.7M in Q2</description>
</item>
<item>
<title>Precipio Announces Q3-2025 Shareholder Update Call</title>
<link>https://6ix.com/company/precipio-inc/news/precipio-announces-q3-2025-shareholder-220000003</link>
<guid isPermaLink="true">https://6ix.com/company/precipio-inc/news/precipio-announces-q3-2025-shareholder-220000003</guid>
<pubDate>Tue, 04 Nov 2025 22:00:00 GMT</pubDate>
<description>Conference Call to be held on November 17th, 2025 at 5:00 PM ESTNEW HAVEN, Conn., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2025 corporate update call on November 17th, 2025 at 5:00 PM ET. The call will include updates on all of the company’s current core businesses. The conference call may be accessed by calling 800.717.1738. All callers should ask for the Precipio conference call. Listeners interested in submitt</description>
</item>
<item>
<title>Precipio Terminates Its ATM</title>
<link>https://6ix.com/company/precipio-inc/news/precipio-terminates-atm-140000076</link>
<guid isPermaLink="true">https://6ix.com/company/precipio-inc/news/precipio-terminates-atm-140000076</guid>
<pubDate>Tue, 02 Sep 2025 14:00:00 GMT</pubDate>
<description>Management Decision Further Reinforces Commitment to Responsible Capital ManagementNEW HAVEN, Conn., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), has terminated its ATM (At-The-Market) instrument with investment bank Alliance Global Partners (AGP). “Our Company is in a much stronger position today than it was when we entered into this structure. With our elimination of negative cash flow from operations, and our recent increases of our ca</description>
</item>
<item>
<title>Precipio Announces its Q2-2025 Financial Results</title>
<link>https://6ix.com/company/precipio-inc/news/precipio-announces-q2-2025-financial-210000152</link>
<guid isPermaLink="true">https://6ix.com/company/precipio-inc/news/precipio-announces-q2-2025-financial-210000152</guid>
<pubDate>Wed, 13 Aug 2025 21:00:00 GMT</pubDate>
<description>Conference call to follow tomorrow, August 14 at 5 PM ESTNEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), filed its 10-Q report today. The following are the highlights of the Company’s financial performance and outlook for 2025. “Yet another quarter of revenue growth in both company divisions, along with overall gross margin improvement, has led to an improved cash performance for the Company. With the remaining repayment of</description>
</item>
<item>
<title>Precipio Announces Q2-2025 Shareholder Update Call</title>
<link>https://6ix.com/company/precipio-inc/news/precipio-announces-q2-2025-shareholder-203000469</link>
<guid isPermaLink="true">https://6ix.com/company/precipio-inc/news/precipio-announces-q2-2025-shareholder-203000469</guid>
<pubDate>Thu, 31 Jul 2025 20:30:00 GMT</pubDate>
<description>Conference Call to be held on August 14th, 2025 at 5:00 PM ESTNEW HAVEN, Conn., July 31, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2025 corporate update call on August 14th, 2025 at 5:00 PM ET. The call will include updates on all of the company’s current core businesses. The conference call may be accessed by calling 800.717.1738. All callers should ask for the Precipio conference call. Listeners interested in submitting</description>
</item>
<item>
<title>Precipio Enters Into Agreement With Warrant Holder To Exercise Majority Of Warrants As Cashless</title>
<link>https://6ix.com/company/precipio-inc/news/precipio-enters-agreement-warrant-holder-203000290</link>
<guid isPermaLink="true">https://6ix.com/company/precipio-inc/news/precipio-enters-agreement-warrant-holder-203000290</guid>
<pubDate>Fri, 11 Jul 2025 20:30:00 GMT</pubDate>
<description>NEW HAVEN, Conn., July 11, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has entered into an agreement with its largest warrant holder, amending the existing structure from cash exercise of warrants, to a revised structure whereby 100,000 warrants (approximately ⅓) shall be exercised with cash, and the remainder (approximately 200,000 warrants) to be exercised in a cashless manner. The transaction accomplishes two things: Reducing the number of share</description>
</item>
<item>
<title>Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting</title>
<link>https://6ix.com/company/precipio-inc/news/precipio-requesting-shareholders-brokers-vote-160000061</link>
<guid isPermaLink="true">https://6ix.com/company/precipio-inc/news/precipio-requesting-shareholders-brokers-vote-160000061</guid>
<pubDate>Mon, 16 Jun 2025 16:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., June 16, 2025 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately today, no later than 11 pm Eastern Time. In order to ensure that there is a quorum required for the shareholders’ meeting that is scheduled to take place tomorrow, June 17, 2025, at 10 a.m. Eastern Time. At the time of this press release, approximately 42% of shares have been vo</description>
</item>
<item>
<title>Precipio Announces its Q1-2025 Financial Results</title>
<link>https://6ix.com/company/precipio-inc/news/precipio-announces-q1-2025-financial-210000773</link>
<guid isPermaLink="true">https://6ix.com/company/precipio-inc/news/precipio-announces-q1-2025-financial-210000773</guid>
<pubDate>Wed, 14 May 2025 21:00:00 GMT</pubDate>
<description>Conference call to follow tomorrow, May 15 at 5 PM ESTNEW HAVEN, Conn., May 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), filed its 10-Q report today. The following are the highlights of the Company’s financial performance and outlook for 2025. “We remain confident in the Company’s trajectory, supported by strong year-over-year revenue growth, improved gross margins, disciplined cost control and increasing operational efficiency”, said Ilan Dani</description>
</item>
<item>
<title>Precipio Announces Q1-2025 Shareholder Update Call</title>
<link>https://6ix.com/company/precipio-inc/news/precipio-announces-q1-2025-shareholder-210000762</link>
<guid isPermaLink="true">https://6ix.com/company/precipio-inc/news/precipio-announces-q1-2025-shareholder-210000762</guid>
<pubDate>Thu, 01 May 2025 21:00:00 GMT</pubDate>
<description>Conference Call to be held on May 15th, 2025 at 5:00 PM ESTNEW HAVEN, Conn., May 01, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q1-2025 corporate update call on May 15th, 2025 at 5:00 PM ET. The call will include updates on all of the company’s current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio, Inc. conferenc</description>
</item>
<item>
<title>Precipio Announces Q4 and year-end 2024 Shareholder Update Call</title>
<link>https://6ix.com/company/precipio-inc/news/precipio-announces-q4-end-2024-210000899</link>
<guid isPermaLink="true">https://6ix.com/company/precipio-inc/news/precipio-announces-q4-end-2024-210000899</guid>
<pubDate>Mon, 17 Mar 2025 21:00:00 GMT</pubDate>
<description>Conference Call to be held on March 31st, 2025 at 5:00 PM ESTNEW HAVEN, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4 and year end 2024 corporate update call on March 31st, 2025 at 5:00 PM ET. The call will include updates on all of the company’s current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Preci</description>
</item>
<item>
<title>Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)</title>
<link>https://6ix.com/company/precipio-inc/news/precipio-achieves-key-q4-2024-143000864</link>
<guid isPermaLink="true">https://6ix.com/company/precipio-inc/news/precipio-achieves-key-q4-2024-143000864</guid>
<pubDate>Tue, 25 Feb 2025 14:30:00 GMT</pubDate>
<description>Both metrics demonstrate the ability to achieve financial independenceNEW HAVEN, Conn., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that it has achieved two important financial goals in the last quarter of 2024: Positive Adjusted EBITDA – Precipio reports (unaudited) Adjusted EBITDA of $0.4M for Q4-2024. Adjusted EBITDA is a non-GAAP metric that comprises EBITDA, less non-cash stock-based compensation expense and other significa</description>
</item>
<item>
<title>Precipio grants senior management performance-based awards instead of traditional time-vested ESOPs</title>
<link>https://6ix.com/company/precipio-inc/news/precipio-grants-senior-management-performance-based-awards-instead-of-traditional-time-vested-esops</link>
<guid isPermaLink="true">https://6ix.com/company/precipio-inc/news/precipio-grants-senior-management-performance-based-awards-instead-of-traditional-time-vested-esops</guid>
<pubDate>Thu, 16 Jan 2025 05:00:00 GMT</pubDate>
<description>These options vest when PRPO stock price is 5x the exercise price NEW HAVEN, Conn., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company</description>
</item>
<item>
<title>Precipio Announces Q3-2024 Shareholder Update Call</title>
<link>https://6ix.com/company/precipio-inc/news/precipio-announces-q3-2024-shareholder-update-call</link>
<guid isPermaLink="true">https://6ix.com/company/precipio-inc/news/precipio-announces-q3-2024-shareholder-update-call</guid>
<pubDate>Wed, 06 Nov 2024 05:00:00 GMT</pubDate>
<description>Conference Call to be held on November 18, 2024, at 5:00 PM EST NEW HAVEN, Conn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company</description>
</item>
<item>
<title>Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping</title>
<link>https://6ix.com/company/precipio-inc/news/precipio-expands-bloodhoundtm-mpn-panel-by-adding-calr-mutation-subtyping</link>
<guid isPermaLink="true">https://6ix.com/company/precipio-inc/news/precipio-expands-bloodhoundtm-mpn-panel-by-adding-calr-mutation-subtyping</guid>
<pubDate>Tue, 08 Oct 2024 04:00:00 GMT</pubDate>
<description>The unique assay enables laboratories to provide clinicians with more informed treatment decisions for their patients NEW HAVEN, Conn., Oct. 08, 2024 (GLOBE</description>
</item>
</channel>
</rss>